Clinical Trials Logo

Clinical Trial Summary

This mechanistic study will test if NAC affects chronic oxidative stress and depletion of antioxidants in GWI participants. Blood specimen collection and neuroimaging will be used to determine whether NAC affects serum glutathione (GSH) concentration and oxidative stress in the CNS when compared to placebo.


Clinical Trial Description

During the 1990-91 Gulf War (GW), military personnel were exposed to numerous chemical and environmental agents during deployment including spraying of pesticides, petroleum combustion products, and nerve gas. Exposure to these chemical and environmental agents can damage cell function and more specifically, mitochondrial function, which negatively affects energy production and can lead to oxidative stress and neuroinflammation. Animal models using similar exposures have documented this in the central nervous system (CNS) compartment. This disruption in mitochondrial function and energy production is likely tied to resulting symptoms of Gulf War Illness (GWI) including fatigue, headaches, joint and muscle pain, gastrointestinal and sleep disturbances, neurologic and neuropsychological symptoms, respiratory issues, and cardiovascular problems. The Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC) plans to evaluate N-Acetyl Cysteine (NAC) as a promising approach to help the CNS recover from chronic oxidative stress and depletion of antioxidants. The Congressionally Directed Medical Research Program's (CDMRP's) two Gulf War Illness Consortiums (GWICs) and others have added to the growing evidence of the role of CNS oxidative stress and neuroinflammation in symptoms of GWI, yet there is little definitive work on the delivery of antioxidants to the CNS environment. In this mechanistic study, we aim to determine if NAC has the ability to target mitochondrial dysfunction and reverse oxidative stress in the CNS. Based on our early experiences with antioxidants in GWI and other complex disease states along with the proven record of NAC in reducing glutathione (GSH) deficits, it is possible that this antioxidant will help to restore mitochondrial function and provide a more targeted approach to improve outcomes in Veterans with GWI. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04987775
Study type Interventional
Source Nova Southeastern University
Contact Nancy Klimas, MD
Phone 9542622855
Email nklimas@nova.edu
Status Recruiting
Phase Early Phase 1
Start date November 30, 2023
Completion date September 2024

See also
  Status Clinical Trial Phase
Completed NCT00129454 - Telemedicine Treatment for Veterans With Gulf War Illness N/A
Completed NCT00100412 - Hyporeactivity and Gulf War Illness N/A
Recruiting NCT04182659 - Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms N/A
Completed NCT03342482 - Glutamate Neuro-Excitotoxicity in GWI N/A
Completed NCT01264471 - Mechanisms of Mitochondrial Defects in Gulf War Syndrome N/A
Terminated NCT03547869 - Transcranial Direct Current Stimulation for Pain Treatment in Gulf War Illness. N/A
Recruiting NCT05675878 - Confirmation of Diet as a Treatment for Gulf War Illness Phase 3
Recruiting NCT05736146 - Validating Gulf War Illness Blood Biomarkers
Completed NCT03560830 - START & STOPP in GWI
Recruiting NCT05355272 - Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) Phase 2
Terminated NCT04712071 - Ketamine in Veterans With Gulf War Illness Early Phase 1
Completed NCT03030794 - Alleviating Headache and Pain in GWI With Neuronavigation Guided rTMS N/A
Completed NCT04638998 - Assessing Neuroinflammation in GWI Using MRS
Completed NCT02804828 - Mitochondrial Cocktail for Gulf War Illness N/A
Recruiting NCT02848417 - Glutathione vs. Curcumin Clinical Trial Phase 1/Phase 2
Recruiting NCT00956150 - Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex Phase 1
Completed NCT00018707 - Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress N/A
Not yet recruiting NCT05992311 - Clinical Evaluation of Montelukast in Veterans With Gulf War Illness Phase 1